Your browser doesn't support javascript.
loading
High-Dimensional Mass Cytometry Analysis of Embryonic Antigens and Their Signaling Pathways in Myeloid Cells from Bone Marrow Aspirates in AML Patients at Diagnosis.
Aanei, Carmen-Mariana; Devêvre, Estelle; Șerban, Adrian; Tavernier-Tardy, Emmanuelle; Guyotat, Denis; Campos Catafal, Lydia.
Afiliação
  • Aanei CM; Laboratory of Hematology, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France.
  • Devêvre E; Santé Ingénierie Biologie Saint-Etienne, INSERM SainBiose U1059, 42270 Saint-Priest-en-Jarez, France.
  • Șerban A; Plateau de Cytométrie AniRA, SFR BioSciences (UAR3444-US8), 69367 Lyon, France.
  • Tavernier-Tardy E; Laboratory of Hematology, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France.
  • Guyotat D; Department of Clinical Hematology, University Hospital of Saint-Etienne, 42100 Saint-Etienne, France.
  • Campos Catafal L; Department of Clinical Hematology, University Hospital of Saint-Etienne, 42100 Saint-Etienne, France.
Cancers (Basel) ; 15(19)2023 Sep 25.
Article em En | MEDLINE | ID: mdl-37835401
ABSTRACT

BACKGROUND:

Embryonic antigens (EA) regulate pluripotency, self-renewal, and differentiation in embryonic stem (ES) cells during their development. In adult somatic cells, EA expression is normally inhibited; however, EAs can be re-expressed by cancer cells and are involved in the deregulation of different signaling pathways (SPs). In the context of AML, data concerning the expression of EAs are scarce and contradictory.

METHODS:

We used mass cytometry to explore the expression of EAs and three SPs in myeloid cells from AML patients and normal bone marrow (NBM). Imaging flow cytometry was used for morphological assessment of cells in association with their OCT3/4 expression status (positive vs. negative).

RESULTS:

An overall reduction in or absence of EA expression was observed in immature myeloid cells from AML patients compared to their normal counterparts. Stage-specific embryonic antigen-3 (SSEA-3) was consistently expressed at low levels in immature myeloid cells, whereas SSEA-1 was overexpressed in hematopoietic stem cells (HSCs) and myeloblasts from AML with monocytic differentiation (AML M4/M5). Therefore, these markers are valuable for distinguishing between normal and abnormal myeloid cells. These preliminary results show that the exploration of myeloid cell intracellular SPs in the setting of AML is very informative. Deregulation of three important leukemogenic SPs was also observed in myeloid cells from AML.

CONCLUSIONS:

Exploring EAs and SPs in myeloid cells from AML patients by mass cytometry may help identify characteristic phenotypes and facilitate AML follow-up.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article